Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenue:
Product sales	$ 2,049,320	$ 1,292,689	$ 3,989,080	$ 2,586,177
Royalties	166,553	306,376	661,903	1,225,602
Licensing revenue	262,690	679,962	788,068	1,947,813
Development fees and other	814,480	722,849	1,464,405	1,201,472
Tarsa revenue	119,658	426,807	998,060	1,062,480
Total revenue	3,412,701	3,428,683	7,901,516	8,023,544
Operating expenses:
Research and development	1,154,302	2,245,000	3,792,335	6,764,287
Cost of goods sold	829,895	493,415	1,528,324	1,028,955
General and administrative	2,402,984	2,121,859	6,661,001	6,766,754
Loss on sale of patents		824,241		824,241
Unallocated facility expenses	712,531	883,617	2,249,930	2,482,790
Total operating expenses	5,099,712	6,568,132	14,231,590	17,867,027
Operating loss	(1,687,011)	(3,139,449)	(6,330,074)	(9,843,483)
Other income (expense):
Interest and other income	9,743	11,052	92,761	62,105
Interest expense	(3,465,175)	(2,815,444)	(9,613,933)	(7,943,686)
Gain (loss) on change in fair value of embedded conversion feature	640,000	3,650,000	(1,870,000)	(12,120,000)
Loss from investment in former China joint venture			(600,000)	(1,375,925)
Loss from investment in Tarsa		(1,301,143)	(650,571)	(2,819,143)
Loss before income taxes	(4,502,443)	(3,594,984)	(12,641,743)	(34,040,132)
Income tax benefit from refund of federal tax credits			26,758
Net loss	$ (4,502,443)	$ (3,594,984)	$ (18,945,059)	$ (34,040,132)
Net loss per share – basic and diluted (in Dollars per share)	$ (0.05)	$ (0.04)	$ (0.20)	$ (0.37)
Weighted average number of shares outstanding - basic and diluted (in Shares)	95,537,312	92,910,238	95,405,110	92,636,692